BIODEXA PHARMA - Key Persons
Dan has 17 years experience in the biotech sector with particular focus on drug delivery and nanotechnologies for oncology. He has managed interdisciplinary R&D programmes across biology, chemistry and engineering. As well as leading Biodexa Pharmaceuticals' exploratory oncology R&D, Dan is responsible for management of Biodexa Pharmaceuticals' intellectual property portfolio.
Dan holds a PhD in Chemistry, an MBA from Imperial College Business School and is a Fellow of the Royal Society of Chemistry.
Job Titles:
- Chief Medical Officer
- Chief Scientific Officer
Dmitry has joined the company in 2021 as a Chief Scientific Officer and is responsible for all R&D activities of Biodexa Pharmaceuticals. He is a medically trained professional with over 17 years of experience in drug and medical devices development.
Prior to joining Biodexa Pharmaceuticals, Dmitry served as a Chief Medical Officer at Oxford Biomedica plc, a company specialising in development products within the cell & gene area. He has also had roles of increasing responsibilities within GSK, Ono Pharma, Daiichi Sankyo and Grunenthal.
Dmitry holds a MD from the Perm State Medical Academy (Russia), a MBA from the Warwick University and a diploma in pharmaceutical medicine from the Universite Libre de Bruxelles.
Job Titles:
- Accountant
- Group Financial Controller
Fiona is a qualified accountant and has held senior finance positions within the PR and advertising industry, including Group Finance Director of Chime Communications Group. Fiona is a Fellow of the Chartered Association of Certified Accountants.
Job Titles:
- VP Head of Clinical Operations
Nicola has over 30 years' global clinical development experience covering all phases in a broad range of therapeutic areas, as well as more specialist cell and gene therapies and medical device development. Prior to joining Biodexa Pharmaceuticals, she has held senior positions in companies such as Oxford Biomedica, Takeda, Ark Therapeutics, Silence Therapeutics (formerly SR Pharma) and Cephalon. Nicola studied Biochemistry and holds a MSc in Pharmacology.
Job Titles:
- Member of the Board of Directors
- Non - Executive Director
Stephen Parker has over 30 years' experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp2 Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.
Job Titles:
- Chairman of the Audit Committee
- Member of the Board of Directors
- Member of the Remuneration Committee
- Senior Independent Non - Executive Director
Dr Turton previously headed Warburg Pincus' healthcare investing activities in Europe and was a principal at Index Ventures in Geneva. He has over 10 years of experience investing in biopharma companies following a ten-year career in the international pharmaceutical industry incorporating roles in research, business development and general management. Dr Turton has an MBA from INSEAD and a Ph.D. in pharmacy from the University of London. He has been a board director of private and public biomedical companies: Archimedes Pharma, Eurand, ProStrakan and Tornier. Dr Turton was most recently chairman of Q Chip prior to its acquisition by the Group. He is currently CEO of Gensmile, a new dental corporate building a group of dental clinics in the UK.
Job Titles:
- Member of the Audit Committee
- Member of the Board of Directors
- Member of the Remuneration Committee
- Non - Executive Chairman
Stephen Parker has over 30 years' experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp2 Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.
Job Titles:
- CEO
- CFO
- Member of the Board of Directors
Mr. Stamp is an experienced public company CFO and has held senior positions in a number of significant healthcare companies including as Group Finance Director of Shire plc, Chief Operating Officer of Xanodyne Pharmaceuticals Inc and most recently with AIM quoted Ergomed plc, where he served initially as CFO before becoming CEO. Mr Stamp qualified as a Chartered Accountant at KPMG and is a member of the Institute of Chartered Accountants.
A chemist by training, Steve has spent more than 30 years in commercially focused roles across multiple sectors of the pharmaceutical industry. Steve has led commercial teams at drug delivery organisations, including Eurand and Bespak, and has held senior roles at speciality pharma companies, Elan, Shire and Theravance Biopharma.
Job Titles:
- VP Head of Clinical Operations
Vincent has over 17 years of experience within the biotech and CRO industries with a keen interest in Oncology and novel therapeutics. He has a breadth of knowledge within Clinical Operations having worked in various roles and sizes of organisation throughout his career, including Quality Assurance. He started his career at large pharma, before moving into the CRO industry and taking a very traditional Clinical Operations career route of Clinical Research Associate and into Project Management. Before joining Midatech Pharma Vince held the position of Vice President, Clinical Operations at the ReNeuron Ltd, where he oversaw Clinical Operations activities of their pipeline.